Inhibition of hepatitis B virus production by Boehmeria nivea root extract in HepG2 2.2.15 cells

被引:39
作者
Huang, Kai-Ling
Lai, Yiu-Kay
Lin, Chih-Chien
Chang, Jia-Ming [1 ]
机构
[1] Dev Ctr Biotechnol, Div Res & Dev, Xizhi City 221, Taipei County, Taiwan
[2] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30013, Taiwan
[3] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 30013, Taiwan
[4] Da Yeh Univ, Dept Bioresources, Changhua 515, Taiwan
关键词
Boehmeria nivea; medicinal herb; antiviral agent; hepatitis B virus; anti-hepatitis B virus; HepG2; 2.2.15;
D O I
10.3748/wjg.v12.i35.5721
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To explore the anti-hepatitis B virus (HBV) effects of Boehmeria nivea (B. nivea) root extract (BNE) by using the HepG2 2.2.15 cell model system. METHODS: Hepatitis B surface antigen (HBsAg), hepatitis B virus e antigen (HBeAg), and HBV DNA were measured by using ELISA and real-time PCR, respectively. Viral DNA replication and RNA expression were determined by using Southern and Northern blot, respectively. RESULTS: In HepG2 2.2.15 cells, HBeAg (60%, P < 0.01) and particle-associated HBV DNA (> 99%, P < 0.01) secretion into supernatant were significantly inhibited by BNE at a dose of 100 mg/L, whereas the HBsAg was not inhibited. With different doses of BNE, the reduced HBeAg was correlated with the inhibition of HBV DNA. The anti-HBV effect of BNE was not caused by its cytotoxicity to cells or inhibition of viral DNA replication and RNA expression. CONCLUSION: BNE could effectively reduce the HBV production and its anti-HBV machinery might differ from the nucleoside analogues. (C) 2006 The WJG Press. All rights reserved.
引用
收藏
页码:5721 / 5725
页数:5
相关论文
共 31 条
[1]   Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase [J].
Angus, P ;
Vaughan, R ;
Xiong, S ;
Yang, HL ;
Delaney, W ;
Gibbs, C ;
Brosgart, C ;
Colledge, D ;
Edwards, R ;
Ayres, A ;
Bartholomeusz, A ;
Locarnini, S .
GASTROENTEROLOGY, 2003, 125 (02) :292-297
[2]   Commonly used herbal medicines in the United States: A review [J].
Bent, S ;
Ko, R .
AMERICAN JOURNAL OF MEDICINE, 2004, 116 (07) :478-485
[3]  
Buster EHCJ, 2006, NETH J MED, V64, P175
[4]  
CARMICHAEL J, 1987, CANCER RES, V47, P943
[5]   A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients [J].
Chang, TT ;
Gish, RG ;
Hadziyannis, SJ ;
Cianciara, J ;
Rizzetto, M ;
Schiff, ER ;
Pastore, G ;
Bacon, BR ;
Poynard, T ;
Joshi, S ;
Klesczewski, KS ;
Thiry, A ;
Rose, RE ;
Colonno, RJ ;
Hindes, RG .
GASTROENTEROLOGY, 2005, 129 (04) :1198-1209
[6]   ACTIVE COMPOUNDS FROM SAUSSUREA-LAPPA CLARKS THAT SUPPRESS HEPATITIS-B VIRUS SURFACE-ANTIGEN GENE-EXPRESSION IN HUMAN HEPATOMA-CELLS [J].
CHEN, HC ;
CHOU, CK ;
LEE, SD ;
WANG, JC ;
YEH, SF .
ANTIVIRAL RESEARCH, 1995, 27 (1-2) :99-109
[7]   Identification of a protein kinase C (PKC) activator, daphnoretin, that suppresses hepatitis B virus gene expression in human hepatoma cells [J].
Chen, HC ;
Chou, CK ;
Kuo, YH ;
Yeh, SF .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (07) :1025-1032
[8]   Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review [J].
Coon, JT ;
Ernst, E .
JOURNAL OF HEPATOLOGY, 2004, 40 (03) :491-500
[9]   Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids [J].
Deres, K ;
Schröder, CH ;
Paessens, A ;
Goldmann, S ;
Hacker, HJ ;
Weber, O ;
Krämer, T ;
Niewöhner, U ;
Pleiss, U ;
Stoltefuss, J ;
Graef, E ;
Koletzki, D ;
Masantschek, RNA ;
Reimann, A ;
Jaeger, R ;
Gross, R ;
Beckermann, B ;
Schlemmer, KH ;
Haebich, D ;
Rübsamen-Waigmann, H .
SCIENCE, 2003, 299 (5608) :893-896
[10]   A PRELIMINARY TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS-B INFECTION [J].
DIENSTAG, JL ;
PERRILLO, RP ;
SCHIFF, ER ;
BARTHOLOMEW, M ;
VICARY, C ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1657-1661